Introduction:
Takayasu arteritis (TA) is a prototypic large vessel vasculitis characterised by granulomatous inflammation of the aorta, its main branches and pulmonary arteries. Untreated inflammation often leads to stenosis and / or occlusion of involved arteries; less frequently, dilatation or aneurysm formations are the sequelae [1, 2] . The disease is rare but somewhat more common in Asians. Over the past 16 years, we have created a database of 503 patients with TA in our tertiary care, teaching hospital. Several clinical series from various parts of the world have highlighted different clinical aspects of this disease; most of these studies are retrospective in nature except one from the NIH and a small Indian series [3, 4] . Arnaud et al, in their multicentre retrospective study from France have looked at the influence of ethnic background on clinical phenotypes of TA, while Yang et al addressed the predictors of survival in Chinese patients. On the other hand, the two recent Japanese studies analysed changes in the profile of TA in the current decade as compared to those diagnosed in the past, as well as the effects of gender and age on clinical manifestations [5] [6] [7] [8] . Even though many case series from various centres across the world have been published, data on long term outcome is negligible and only small series of patients exist with ≥ 1year follow up. Schmidt et al from Mayo clinic described 126 patients with TA, but the outcome data was available only for 79 of them [9] . There is no long term study even from South Asia including India, one of the largest reservoirs of TA. We report here the outcome data of 251 patients from our single centre cohort of TA, restricted to patients with follow up duration of at least 12 months.
In this study, we analysed both retrospectively and prospectively, the outcome of treatment in TA by objective instruments.
Materials and Methods:

Data extraction:
The data for this study has been collected in retrospective manner from our institute's electronic medical records (EMR) for 179 patients and prospectively for the rest of the cohort (n=72). EMR include the records of all discharge summaries, outpatient medical reports and investigation reports in an electronic workstation by our institute and it is in existence since the year 2002. In addition, doctors' notes and inpatient case records are also saved as hard copies. Scanned documents are also preserved as soft copies for all patients attending this hospital since 2012; these can be retrieved and made available for clinical research after approval from the institute research and ethics committee, Thus, the data in these records has been prospectively entered and saved, but have been extracted for this study in a retrospective manner.
Patients:
A total of 503 patients with TA, attending our outpatient and in-patient services during the period from January, 1998 to April, 2016 and satisfying the 1990 ACR criteria, Ishikawa criteria or Sharma's modification of Ishikawa criteria or EULAR/PRESS criteria for childhood TA were studied [10] [11] [12] . Of these, 251 consecutive patients had complete records of clinical details with a follow up duration of at least 12 months and therefore, were eligible to be included in this study. Details of demography, clinical as well as angiographic features, extent of clinical disease assessed by DEI.Tak, cumulative damage assessed by TADS (Takayasu arteritis damage score), disease activity assessed by ITAS2010 (Indian Takayasu activity score, 2010) along with laboratory parameters i.e. C-Reactive Protein (CRP) and Erythrocyte sedimentation rate (ESR) were noted for each visit till the last recorded follow up.
Disease assessment:
The disease was categorised into 5 subtypes according to Hata's classification criteria based on angiographic findings [13] . The baseline extent of disease was assessed by DEI.Tak score [14, 15] .
During the follow up visits, we defined disease activity by a hybrid composite score namely, ITAS-A(CRP) which incorporates both clinical assessment by ITAS-2010 and CRP as biomarker [16] .
Study definitions:
Juvenile onset TA was defined as TA patients with onset of 1 st symptom at or prior to the age of 16 years, while those with age of onset beyond 16 years of age were labelled as adult onset TA.
Disease activity at each visit was defined as 
Response to Treatment was classified as
A. Complete response (CR):
absence of all of these criteria of disease activity as mentioned above When the patient maintained complete response throughout the follow up period, the outcome was called persistent complete response.
The subset of patients with persistent CR during the entire follow up period, who were able to reduce daily steroid dose to ≤ 5mg, were classified as having sustained inactive disease.
B. Partial response (PR) was defined as ITAS-A (CRP) value of 1 or 2 along with any improvement in disease activity by any of the 3 categories of criteria as above, not amounting to complete normalisation. This included downward trend from baseline activity by clinical, imaging or laboratory criteria.
If a patient attained CR or PR anytime during study period, whether early or late, they were considered as treatment responders.
C. Relapsing-remitting disease:
Patients who had return of disease activity as defined above after having attained complete response.
D. Refractory disease:
Inability to achieve CR or PR during the entire follow up period in spite of treatment escalation as per our protocol.
Medical Therapy protocol:
The patients in our study were treated by medical therapy according to protocol adopted by our unit based on clinical, real life efficacy and socioeconomic background relevant to our resource limited set up. The treatment protocol is depicted in figure-1 Predictors of sustained inactive disease were identified using regression analysis. A prediction model has also been constructed incorporating the parameters which were significant to the precision levels of 10% in regression analysis. Area under curve (AUC) for individual predictors as well as the prediction model were generated by constructing receiver operating curves (ROC) and optimal cut off values were determined. The overall survival and relapse free survival were projected by Kaplan Meir survival curve.
Wherever applicable, Cox proportional hazards regression plot was used to compare the efficacy of medications on disease course. SPSS version 16 was used for all analysis.
Results:
Baseline demography and disease extent:
In total, 251 patients with follow up details of ≥ 1 year were included in this study. Majority (n=205, 81.7%) were females with mean age at 1 st visit to our clinics of 29.2 ± 11.8 years and mean age at onset of symptoms of 24 ± 11.0 years. Median duration of disease prior to presentation to us was 24 (6-70) months. At baseline, the most common clinical presentations included pulse loss, claudication, and hypertension which were noted in 60.6%, 59% and 53.4% of patients respectively (supplementary figure-S1). Detailed angiography was done for all but 3 patients; 9 of them had undergone only CT/MR angiogram, while the remaining vast majority had undergone conventional angiography (supplementary figure-S2). Type V disease was the commonest type (n=135, 54.2%) followed by type 4 and type 1 (n=45, 18% each). The commonest comorbidity was tuberculosis in 26 patients; diabetes mellitus was present in 6 patients.
Median DEI.Tak was 9 (IQR: 6-13 Altogether, 81 patients (32.3%) had present or prior history of major complications at the time of presentation to our unit; of these, hypertensive emergency including accelerated hypertension, cerebrovascular accident and aortic regurgitation were the most common ones. Only two fatalities were observed in the whole cohort during the study period; one patient expired due to sepsis following a osteoporotic vertebral fracture and another patient with underlying dilated cardiomyopathy had succumbed to acute pulmonary edema.
Treatment details:
One patient had developed acute myeloid leukemia (at 50 years of age) during 48th month of follow up and was excluded from analysis, though the patient was alive till the last follow up visit.
Among the initial non-responders, 19 patients eventually responded (CR in 16, PR=in 3) after escalating steroid dose with or without addition of biological agent TCZ (n=9). Thus, of the entire cohort, only 15 patients (6%) did not attain complete or partial response anytime during follow up, in-spite of treatment escalation.
The Kaplan Meir curve showed cumulative relapse free survival to be 93%, 73%, 66% and 52% at 1 year, 3 years 5 years and 10 years respectively (figure-3A). During any follow up interval period, initial high overall response rate (CR+PR) was noted to persist consistently (figure 3B). Even the lowest overall response rate was 68.2% during 8-24 months follow up period; beyond 2 years this figure peaked to ≈ 80% till the last follow up. of whom had isolated angiographic progression without clinical and laboratory criteria. 
Discussion:
This is the largest single centre study describing long term outcome of a large cohort of patients with TA. We studied 251 patients over a median follow up period of 42 (IQR: 24-81) months using objective instruments like ITAS-A(CRP), TADS, other common biomarkers and angiography. We used steroid sparing immunosuppressants (predominantly Mycophenolate) from the beginning along with tapering schedule of steroid (predominantlly Deflazacort, an oxazoline derivative of prednisolone). In some cases with aggressive disease, we used TCZ for rapid control of disease activity and could achieve significant steroid sparing action. With this strategy, the majority (92.8%) of our patients had at least one period of stable disease (complete or partial response), and only 7.2% of our cohort had disease truly refractory to treatment till the last follow up (figure 2).
At the very first follow up evaluation after initiation of our immunosuppression protocol, 215 patients (86.7%) responded to treatment by our response criteria defined in the methodology, with complete response in176 (70.1%) and partial response in 42 patients (16.7%). Only 36 patients (14.3%) were non-responders at that point of follow up.
The initial complete response mentioned above was sustained throughout the entire follow up period in 65.9% of these responders in-spite of de-escalation of treatment as per our protocol (46.2% of the entire cohort). This was much higher than the figure of 17% reported in an earlier series from the Cleveland clinic foundation (CCF). In the CCF cohort, steroid sparing immunosuppressant was added only after patients relapsed on tapering of steroids [17] (figure-5). These 2 contrasting results emphasise the role of upfront use of steroid sparing immunosuppressant along with steroid from the very initial phase of treatment. 
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Only 22.3% of our patients with initial complete response had relapsed on de-escalation of therapy as per our protocol, which is less than half of that reported by Schmidt et al (46%) [9] . The cumulative relapse free survival (sustained remission) at 1, 3, 5 and 10 years in our study were 93%, 73%, 66% and 52% respectively. Escalation of treatment led to response even in the relapsed patients. Nearly 80% of patients had CR or PR (2/3 rd had CR) at all the time intervals of follow up (figure 3B).
In 34.6% of our patients, sustained inactive disease was observed throughout the follow up period with steroid dose of ≤ 5mg/day at the last follow up visit.
Use of steroid sparing immunosuppressants in TA for maintenance of response has gained increased acceptance in recent times as compared to the past. Earlier reports from Mexico, Japan and India reported use of these agents only in minority of cases, in contrast to their use in >60% of TA patients in recently published series from France and USA [7, 9, [18] [19] [20] [21] . Our policy of concurrent initiation of immunosuppressants at the outset along with steroids in majority of our patients (97.3%) may be the reason for better long term response in our cohort. This was in contrast to the modest results of CCF cohort, who were subjected to sequential approach with initial steroid alone therapy followed by the introduction of steroid sparing second line immunosuppressants only in those patients with relapsing disease [17] .
In addition, we followed a slow taper schedule of steroid therapy in our patients, as faster rate of reduction in steroid dose has been noted to be associated with relapsing disease [6] . Timely revascularisation procedures in our centre could have also contributed to good outcome by preventing ischaemic complications, as noted by Ishikawa et al [21] . Use of mycophenolate was much higher in our cohort as compared to other centres including CCF where methotrextae was the preferred 2 nd line agent. We practise upfront institution of MMF, due to its higher safety data as well as its efficacy comparable to cytotoxics like cyclophosphamide in other autoimmune situations; our earlier study as well as the recent meta-analysis also reported efficacy of MMF in TA [22, 23] . Therefore, it is likely that MMF along with steroids may have added to better outcome in our patients. We did not come across any serious adverse event with the use of MMF, whereas cytopenia requiring hospitalisation was significant amongst our patients receiving azathioprine (n=12 out of 54, p 0.01).
Unlike other autoimmune diseases like lupus, inflammation in TA is thought to be more smoldering, though such presumptions could be due to lack of well-designed controlled trials and outcome studies. Based on real life observations in our large clinic and a recent study by It is also reassuring that most of these patients with such grumbling course had also responded to aggressive breakthrough treatment as per our protocol.
Medical treatment, predominantly comprising of deflazacort and mycophenolate in the vast majority of our patients with TA could also arrest or minimise damage progression in 68% of patients as assessed by TADS score. The increment in damage was directly associated with persistent disease activity, thereby emphasizing the importance of strict and sustained control of disease activity in TA. There were only 2 fatalities (1.3%) in our total cohort, figures much lower than that published in literature.
Heterogeneity in definition of outcome measures renders comparison between various large series of TA difficult. Sustained inactive disease and sustained CR were objectivised as primary outcomes in our study, somewhat similar to the long term outcome measures addressed in the series by Cleveland clinic foundation. Such stringent outcome measure is desirable in a disease like TA, as clinically stable disease may have subclinical histological inflammation with disease progression in 20% to 40% of such patients [17] .
Use of more recent objective tools to define disease extent, activity and damage progression are the strengths of this study. We have used ITAS-2010, a tool validated amongst Indian patients, along with laboratory and angiographic details to assess disease activity in contrast to studies from USA, France and China who used NIH criteria [3, 5, 7, 9, 16, [17] [18] [19] [20] [21] . The major limitation of our study is the retrospective component of our study.
Overall, it was pleasing to note that only 15 of 251 patients were truly refractory to treatment till the last follow up; the vast majority had favourable long term outcome and were responsive to our medical treatment protocol with immunosuppression with or without biologics therapy.
Further, we could define the predictors of sustained inactive disease which may act as a useful model for future studies. Our attempt to develop such a prediction model identified low baseline ESR, CRP, low DEI.Tak scores and type 4 TA as predictors of sustained inactive disease with a sensitivity of 70% and a specificity of 61.1%. On the other hand, isolated abdominal aorta involvement and lower age of onset were found to be negative predictors of persistently refractory disease.
Randomised controlled trial or observational prospective cohort study with the aim to determine long term outcome using uniform treatment protocol is a need of the hour.
Conclusions:
Combination of tapering steroids and steroid sparing immunosuppressants like MMF from the beginning was our primary medical regimen in TA. Biologics like TCZ was used only in select situations as a breakthrough option for rapid control of disease activity.
Our strategy could stabilise disease activity in 92.8% of our patients at various time points of follow up; only 7.2% of our cohort were truly refractory to treatment. We could achieve 93%, 73%, 66% and 52% relapse free survivals at 1 year, 3 year, 5 year and 10 year respectively.
Damage progression was also arrested in 68% of our patients and only 2 fatalities were observed in this cohort. Initial steroid dose of 0.5mg/kg/day with slow taper had similar response and relapse rate as 1mg/kg/day dose. MMF was the cornerstone steroid sparing immunosuppressant and the major maintenance agent to prevent relapses with better safety profile.
